Changyu Medicine Completes ¥250 Million Series D Funding Round
Changyu Medicine has announced the successful completion of its Series D financing round, securing 250 million RMB. The funding was jointly led by Yifeng Capital and Goalida Investment, with participation from other institutions including Jiaxing Yuanfan and Real Capital Global. Qidian Capital served as the financial advisor for the transaction. The capital raised will be primarily allocated to support the Phase III clinical trial of Changyu Medicine's lead product, XG005, for acute pain in the United States. Additionally, the funds will facilitate the ongoing development of the company's core product pipeline and advance its global expansion efforts.
This Series D funding round for Changyu Medicine highlights continued investor confidence in the biopharmaceutical sector, particularly for companies advancing novel therapies through late-stage clinical trials. The significant capital infusion, totaling 250 million RMB, underscores the strategic importance of XG005's Phase III trials in the U.S. market for acute pain. Such investments reflect a broader trend where venture capital and institutional investors are seeking to capitalize on the potential of innovative drug development, especially for conditions with substantial unmet medical needs. The focus on global advancement suggests a long-term strategy to establish a significant international market presence, navigating complex regulatory landscapes and market access challenges.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.